Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000781200 | SCV000919086 | likely pathogenic | Hyper-IgM syndrome type 1 | 2018-02-20 | criteria provided, single submitter | clinical testing | Variant summary: CD40LG c.632C>A (p.Thr211Asn) results in a non-conservative amino acid change located in the Tumor necrosis factor domain (IPR006052) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 87498 control chromosomes in ExAC, however these data do not allow any conclusion about variant significance. c.632C>A has been reported in the literature in one individual affected with Hyper IgM Syndrome Type 1 (Allen 1993). At least one publication reports experimental evidence evaluating an impact on protein function (Allen 1993). The most pronounced variant effect results in <10% of normal activity. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |